Donovan, K., Herrington, W., Haynes, R., Sardell, R., Baigent, C., Holmes, M., & Staplin, N. (2022). Fibroblast growth factor-23 and risk of cardiovascular diseases: A Mendelian randomization study. American Society of Nephrology.
Chicago-viite (17. p.)Donovan, K., W. Herrington, R. Haynes, R. Sardell, C. Baigent, M. Holmes, ja N. Staplin. Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study. American Society of Nephrology, 2022.
MLA-viite (9. p.)Donovan, K., et al. Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study. American Society of Nephrology, 2022.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.